000 | 01876 a2200505 4500 | ||
---|---|---|---|
005 | 20250516195103.0 | ||
264 | 0 | _c20141110 | |
008 | 201411s 0 0 eng d | ||
022 | _a1744-7607 | ||
024 | 7 |
_a10.1517/17425255.2014.883379 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aVadlapatla, Ramya Krishna | |
245 | 0 | 0 |
_aClinically relevant drug-drug interactions between antiretrovirals and antifungals. _h[electronic resource] |
260 |
_bExpert opinion on drug metabolism & toxicology _cApr 2014 |
||
300 |
_a561-80 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review | ||
650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdrug therapy |
650 | 0 | 4 | _aAlkynes |
650 | 0 | 4 |
_aAnti-Retroviral Agents _xtherapeutic use |
650 | 0 | 4 |
_aAntifungal Agents _xtherapeutic use |
650 | 0 | 4 |
_aBenzoxazines _xtherapeutic use |
650 | 0 | 4 |
_aCarbamates _xtherapeutic use |
650 | 0 | 4 | _aCyclopropanes |
650 | 0 | 4 | _aDrug Interactions |
650 | 0 | 4 | _aDrug Monitoring |
650 | 0 | 4 |
_aEchinocandins _xtherapeutic use |
650 | 0 | 4 | _aFurans |
650 | 0 | 4 |
_aHIV Infections _xcomplications |
650 | 0 | 4 |
_aHIV Protease Inhibitors _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aItraconazole _xtherapeutic use |
650 | 0 | 4 |
_aMycoses _xcomplications |
650 | 0 | 4 |
_aOrganophosphates _xtherapeutic use |
650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
650 | 0 | 4 |
_aRitonavir _xtherapeutic use |
650 | 0 | 4 |
_aSulfonamides _xtherapeutic use |
650 | 0 | 4 |
_aTriazoles _xtherapeutic use |
650 | 0 | 4 | _aVoriconazole |
700 | 1 | _aPatel, Mitesh | |
700 | 1 | _aPaturi, Durga K | |
700 | 1 | _aPal, Dhananjay | |
700 | 1 | _aMitra, Ashim K | |
773 | 0 |
_tExpert opinion on drug metabolism & toxicology _gvol. 10 _gno. 4 _gp. 561-80 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1517/17425255.2014.883379 _zAvailable from publisher's website |
999 |
_c23539459 _d23539459 |